Advances in genomic technologies in the last decade have revolutionised the field of medicine, especially in cancer, by producing a large amount of genetic information, often referred to as Big Data. The identification of genetic predisposition changes, prognostic signatures, and cancer driver genes, which when mutated can act as genetic biomarkers for both targeted treatments and disease monitoring, has greatly advanced our understanding of cancer. However, there are still many challenges, such as more sophisticated analysis tools and higher processing capacity, along with cheaper storage and faster and more efficient data transfer, that must be overcome before personalised medicine finally becomes a reality.